Anuncio
Anuncio
TSHA
Taysha Gene Therapies, Inc. Common Stock
4.97
USDPatrocinado
-0.17
-3.37%
09 ene, 15:59 UTC -5
Cerrado
Post-mercado
4.94
-0.03
-0.54%
Informes de beneficios de TSHA
Ratio de Sorpresa Positivo
TSHA superó 10 de las últimas 21 estimaciones.
48%
Próximo informe
Fecha del próximo informe
24 feb 2026
Estimate for Q4 25 (Revenue/ EPS)
$2.10M
/-$0.09
Cambio implícito desde Q3 25 (Revenue/ EPS)
--
/--
Cambio implícito desde Q4 24 (Revenue/ EPS)
+3.95%
/+28.57%
Taysha Gene Therapies, Inc. Common Stock earnings per share and revenue
On 04 nov 2025, TSHA reported earnings of -0.09 USD per share (EPS) for Q3 25, Inline the estimate of -0.09 USD, resulting in a 0.00% surprise. Revenue reached --, compared to an expected 1.41 millón, with a -100.00% difference. The market reacted with a -4.26% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 15 analistas forecast an EPS of -0.09 USD, with revenue projected to reach 2.10 millón USD, implying an aumentar of 0.00% EPS, and -- of --% in Revenue from the last quarter.
Preguntas frecuentes
What were Taysha Gene Therapies, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Taysha Gene Therapies, Inc. Common Stock reported EPS of -$0.09, missing estimates by 0%, and revenue of $0.00, -100% below expectations.
How did the market react to Taysha Gene Therapies, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -4.26%, changed from $4.46 before the earnings release to $4.27 the day after.
When is Taysha Gene Therapies, Inc. Common Stock expected to report next?
The next earning report is scheduled for 24 feb 2026.
What are the forecasts for Taysha Gene Therapies, Inc. Common Stock's next earnings report?
Based on 15
analistas, Taysha Gene Therapies, Inc. Common Stock is expected to report EPS of -$0.09 and revenue of $2.10M for Q4 2025.
Which companies are reporting earnings today?
Cheque FXEmpire's Earnings Calendar for today's list of reporting companies.
Anuncio